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ABSTRACT
Background Cumulative light exposure is significantly
associated with progression of age-related macular
degeneration (AMD). Inhibition of vascular endothelial
growth factor is the main target of current antiangiogenic
treatment strategies in AMD. However, other growth
factors, such as platelet-derived growth factor (PDGF)
and placenta growth factor (PlGF), have a substantial
impact on development of AMD. Previous reports
indicate that sorafenib, an oral multikinase inhibitor,
might have beneficial effects on exudative AMD. This
study investigates the effects of sorafenib on light-
induced overexpression of growth factors in human
retinal pigment epithelial (RPE) cells.
Methods Primary human RPE cells were exposed to
white light and incubated with sorafenib. Viability,
expression, and secretion of VEGF-A, PDGF-BB, and PlGF
and their mRNA were determined by reverse
transcription-polymerase chain reactions,
immunohistochemistry and enzyme-linked
immunosorbent assays.
Results Light exposure decreased cell viability and
increased expression and secretion of VEGF-A, PDGF-BB
and PlGF. These light-induced effects were significantly
reduced when cells were treated with sorafenib at
a dose of 1 mg/ml.
Conclusion The results show that sorafenib has
promising properties as a potential antiangiogenic
treatment for AMD.
INTRODUCTION
Exudative age-related macular degeneration (AMD)
is a leading cause of visual deterioration and legal
blindness in people over the age of 60 in developed
countries.1 Early stages of this disease are charac-
terised by the formation of drusen and atrophic
changes in the retinal pigment epithelium (RPE).1
With progression of the disease, 10% of patients
develop ‘wet’ forms of AMD due to choroidal
neovascularisation (CNV) that often leads to
a rapid loss of vision.1 AMD is a multifactorial
disease with several risk factors for development
and progression, including ethnicity, gender,
smoking, hypertension, genetics, diet and sunlight
exposure.1e4
CNV in the macular region often results in
significant loss of central vision and high-resolution
visual acuity, and is the fundamental pathophysi-
ological process underlying this disease.5 6 Without
treatment, AMD can lead to irreversible loss of the
ability to read, recognise faces, and drive.5 6
Upregulation of vascular endothelial growth
factor (VEGF) is a major critical event in the
development of CNV.7 Therefore, inhibition of
VEGF is the main target of the currently used
antiangiogenic agents in the treatment of AMD.8
The mechanism of action of these VEGF inhibitors
(eg, bevacizumab and ranibizumab) is blocking
VEGF in the extracellular space and thereby
preventing access to its receptor.9 Studies have
demonstrated that treatment of AMD with VEGF
inhibitors is safe and effective.10e12 However, major
prospective randomised trials revealed that despite
an improvement in visual acuity, the neovascular
tissue typically does not regress with VEGF inhi-
bition alone, and without continuous treatment
often reprogression occurs.10 11 The reason for this
lack of sustained effect might be due to redundant
pathways. Previous studies indicated that several
angiogenic growth factors, including platelet-
derived growth factor (PDGF) and placenta growth
factor (PlGF), are overexpressed in the vitreous and
retinas in proliferative retinal disease and play
a crucial role in the development and progression of
AMD.13e16 The reason for this could be that other
molecular pathways remain active, and binding
VEGF in the extracellular space alone might have
only limited effect on neovascular tissue. In addi-
tion, inhibition of a single molecule could induce
a compensatory increase in stimulatory increase of
alternative pathways.
Sorafenib (Nexavar, BAY 43-9006) is an oral
multikinase inhibitor, approved for the treatment
of several forms of cancer.17 Previous case reports
indicate that sorafenib, alone or in combination
with other angiostatic drugs, might have a benefi-
cial effect on exudative AMD.18 19
This study was designed to investigate the effect
of sorafenib on light-induced growth factor
expression in the RPE, which plays a key role in the
development and progression of AMD.1 Therefore,
we exposed primary human RPE cells to wide-band
white light (spectral range 400e700 nm). Cells
were treated with sorafenib and the drug’s effects
on viability of the cells after light exposure was
investigated. Expression of VEGF-A, PDGF-BB and
PlGF was determined.
METHODS
Materials
Sorafenib (Nexavar, BAY 43-9006 [N-(3-trifluor-
omethyl-4-chlorophenyl)-N-(4-(2-methylcarbamoyl
pyridin-4-yl)oxyphenyl)urea]) was dissolved in
100% dimethyl sulfoxide (DMSO; Sigma, St Louis,
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Missouri) and diluted with DMSO, and the cell culture medium
to the desired concentration with a final DMSO concentration
of 0.1% for in vitro studies. DMSO was added to cultures at
0.1% (v/v) as a solvent control.
Ethics
The methods of securing human tissue were humane, included
proper consent and approval, complied with the Declaration of
Helsinki and were approved by the local ethics committee.
Human RPE cell culture
Primary RPE cells from four human donors (48, 52, 56 and
74 years old, obtained 3e10 h postmortem) without any history
of eye disease were obtained from the Eye Bank of Ludwig
Maximilian University and were prepared as previously
described.20 Dulbecco modified Eagle medium (DMEM;
Biochrom, Berlin, Germany) supplemented with 10% fetal calf
serum (FCS; Biochrom) was used as the cell-culture medium. An
increased accumulation of lipofuscin is a common characteristic
of ageing RPE cells in vivo, and lipofuscin is known to act as
a photosensitiser. It has been implicated to play a certain role in
the development and progression of AMD.21e23 To investigate
the effects of white light on RPEs growth factor expression, we
used primary RPE cells of passages 2 and 3 for our experiments.
All investigated RPE cell cultures presented intracellular
pigmented granules in phase-contrast microscopy. These gran-
ules contain, besides melanin and other pigments, a certain
amount of lipofuscin. This characteristic disappears when RPE
cells are cultured for long-term periods.24e26
Cell culture treatment
For all cell-culture experiments, RPE cells were seeded in 35 mm
tissue culture dishes and cultured on confluence in darkness. RPE
cells were kept for 24 h in serum-free conditions. After the cells
were washed with phosphate-buffered saline (PBS), they were
illuminated for 60 min. Directly after illumination, PBS was
replaced with serum-free cell culture medium, and sorafenib was
added with a final concentration of 1 mg/ml.
Illumination of cells
A spot-light source (LC-8; Hamamatsu Photonics, Shizuoka,
Japan) from a mercuryexenon lamp equipped with an optic
fibre as the light guide (spectral range: 400e700 nm) was used
for illumination. The cell-culture medium was replaced with
PBS just before illumination. The plastic cover of the illuminated
cell culture well was removed, and the cells were illuminated
from above. They were illuminated (300 mW/cm2) for 60 min.
The illumination power and spectral range were measured with
a spectrometer (C10083MD; Hamamatsu Photonics). Directly
after illumination, PBS was replaced by serum-free cell culture
medium, sorafenib was added with a final concentration of 1 mg/
ml, and the cells were kept in darkness for another 24 h. Then,
the methylthiotetrazole (MTT) assay, ELISA for detection of
growth factor concentrations in cell culture supernants,
epifluorescence microscopy, phase-contrast microscopy and
RNA isolation were performed.
MTT assay
The tetrazolium dye-reduction assay (MTT; 3-[4,5-dimethylth-
iazol-2-yl]-2,5-diphenyl tetrazolium bromide) was used to
determine the cell survival rate. The MTT test, which is well
established for the assessment of cell viability, was performed as
described by Mosmann,27 with some modifications. The
medium was removed, the cells were washed with PBS, and
1000 ml of MTT solution (1.5 ml MTT stock, 2 mg/ml in PBS,
plus 28.5 ml MEM) was added to each well. RPE cells were
incubated at 378C for 1 h. The formazan crystals that formed
were dissolved by the addition of 1000 ml DMSO per well.
Absorption was measured by a scanning multiwell spectropho-
tometer at 550 nm (Molecular Probes, Eugene, Oregon). The
results were expressed as the mean percentage of proliferation in
the control.
To investigate the effects of different sorafenib concentrations
on RPE cell viability, cells were brought to confluence, kept
under serum-free conditions for 24 h and then were treated with
sorafenib concentrations of 0.5, 1, 1.25, 2.5, 5, 7.5, 10, 12.5, 15,
25 and 50 mg/ml for another 24 h. Then, the MTT assay was
performed. To investigate the effects of sorafenib on RPE cell
viability after light exposure, cells were illuminated and treated
as described above. At 24 h after illumination, the MTT assay
was performed.
The experiments were performed in triplicate and repeated
three times. The control cells were RPE cells of the same passage;
they were kept in darkness, without exposure to any radiation.
Detection of VEGF-A, PDGF-BB and PlGF secretion by RPE cells
RPE cell cultures were grown to confluence and treated as
described. Levels of VEGF-A, PDGF-BB and PlGF in the culture
supernatants were determined by ELISA. The supernatants were
collected after 24 h, and the levels of VEGF-A, PDGF-BB and
PlGF were quantified using a VEGF-A, PDGF-BB or PlGF
Quantikine ELISA Assay Kit (R & D Systems, Minneapolis,
Minnesota) according to the manufacturer ’s instructions.
RNA isolation and real-time PCR
Total RNA was isolated from 10 cm Petri dishes by the guani-
dium thiocyanateephenolechloroform extraction method
(Stratagene, Heidelberg, Germany). The structural integrity of
the RNA samples was confirmed by electrophoresis in 1% Tris-
acetate-EDTA agarose gels. The yield and purity were deter-
mined photometrically (BioPhotometer; Eppendorf, Hamburg,
Germany). Real-time PCR enables quantitative detection of
small amounts of mRNA. After the usual isolation of mRNA,
this mRNA was transferred to complementary DNA (cDNA)
through reverse transcriptase (RT). This cDNA was then used
for the specific PCR. Quantification of VEGF-A, PDGF-BB and
PlGF mRNA was performed with specific primers with a Light-
Cycler instrument (LightCycler System; Roche Diagnostics,
Mannheim, Germany). Primers and probes were detected with
ProbeFinder 2.04. All primers and probes were designed to cross
intron/exon boundaries to avoid amplification of genomic DNA.
All PCR products were sequenced to ensure product validity.
Each 14 ml reaction volume contained 13FastStart DNA Master
Hybridisation Probes Mix (Roche Diagnostics), 4 mM MgCl2,
0.5 mM of each primer, 0.2 mM TaqMan probe and 2 ml cDNA.
The amplification signals were detected in real time, which
allowed accurate quantification of the amounts of the initial
RNA template, because the system can select signals easily
during the exponential amplification phase of PCR. The cDNA
of RPE cells, either after incubation with sorafenib or untreated
and then exposed to light, was amplified with specific primers
for 40 cycles. Two oligonucleotides with different labelled fluo-
rophores were hybridised to the amplified fragment during the
annealing phase. When the two probes came into close prox-
imity, fluorescence resonance energy transfer (FRET) developed
between the two fluorophores. The emitted fluorescence was
then measured by the LightCycler instrument. Hybridisation
probes were displaced during the extension step. Depending on
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the initial concentration of target genes, the signal intensity
increased in different cycles, and these cycles were used as the
crossing point. The standard curve was made with three
different probes of untreated RPE cells. For normalisation of
differences in the amount of total RNA added to each reaction,
18S rRNA was simultaneously processed in the same sample as
an internal control. The level of VEGF-A, PDGF-BB and PlGF
mRNA was determined as the relative ratio (RR), which was
calculated by dividing the level of VEGF-A, PDGF-BB and PlGF
mRNA by the level of the 18S rRNA housekeeping gene in the
same samples. The ratios are expressed as decimals. All experi-
ments were performed at least in triplicate and repeated three
times. Table 1 lists the primers used for RT-PCR.
Immunohistochemistry of RPE cell cultures
Cultured RPE cells were grown on microscope slides and treated
as described above. After incubation, cells were fixed with 4%
phosphonoformic acid (PFA) for 15 min and subsequently
washed twice with PBS containing 0.1% Triton X-100. Primary
incubation of all samples was performed with a mouse anti-
human VEGF-A antibody (Santa Cruz Biotechnology, Santa
Cruz, California), a mouse antihuman PDGF-B antibody (Santa
Cruz Biotechnology) and a goat antihuman PlGF antibody
(Santa Cruz Biotechnology), diluted 1:200 in PBS for 4 h at room
temperature. After washing three times, the culture dishes and
sections were further processed with a Texas Red-conjugated
rabbit antimouse secondary antibody or a fluorescein-conjugated
rabbit antigoat secondary antibody (diluted 1:500 in PBS; Santa
Cruz Biotechnology) for 1 h at room temperature, rinsed in PBS
and mounted with Kaiser ’s glycerine jelly (Merck, Darmstadt,
Germany). Slides were investigated with a Zeiss Axio Imager
fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany).
All experiments were performed at least nine times with RPE
cells from three different cell cultures.
Statistical evaluation
All data were analysed with SPSS 13.0 for Windows (SPSS,
Chicago, Illinois). For all statistical tests, p<0.05 was considered
significant. Results of the MTTassay are presented as mean (SD)
units of absorbance. Ten individual samples per group were
measured in triplicate. The ManneWhitney test was used.
Results from VEGF-A, PDGF-BB and PlGF ELISA are presented
as mean (SD) ratios of each tested probe, which were normalised
to the control. Results of the RT-PCR are presented as mean
(SD) ratios of the investigated mRNA and 18S rRNA. Again,
ManneWhitney testing was applied; all experiments were
performed at least in triplicate and repeated three times.
RESULTS
Viability of cells
Testing concentrations of sorafenib in primary RPE cells
No gross abnormalities, such as abnormal shape and appearance,
cellular lysis, cellular death or other abnormalities, were detected
with phase-contrast microscopy up to a concentration of
12.5 mg/ml sorafenib in primary RPE cells after 24 h treatment.
The number of cells counted in phase-contrast microscopy
correlated well with the quantitative results of the MTT test.
MTT assay
Sorafenib showed no significant toxic effects in the investigated
RPE cell cultures (24 h exposure) at concentrations between 0.5
and 12.5 mg/ml. No significant decrease (Wilcoxon with
a correction for multiple testing) in cellular viability was
detected with RPE cells compared with the control. Concen-
trations of sorafenib between 15 and 25 mg/ml showed an
increasing reduction in cell viability, but still >60% of the cells
revealed activity. At a sorafenib concentration of 50 mg/ml,
a more rapid, dose-dependent and significant reduction in
viability was seen (figure 1).
Testing the effects of sorafenib on viability of RPE cells
after light exposure
When cells were illuminated with unfiltered white light
(300 mW/cm2) for 60 min, a significant reduction in RPE cell
viability was detected (figure 2). In contrast, cells treated with
sorafenib, 1 mg/ml, immediately after illumination showed
a significantly smaller less decrease in viability compared with
cells that were not treated with sorafenib (figure 2).
Expression of VEGF-A, PDGF-B and PlGF mRNA
VEGF-A, PDGF-BB and PlGF mRNA expression was detected in
every sample. All detected mRNA levels of VEGF-A, PDGF-BB
and PlGF were normalised to those of 18S rRNA; the values are
expressed as the RR of VEGF-A/18S, PDGF-BB/18S or PlGF/18S.
Illumination with white light for 60 min led to a significant
Table 1 Primers used for RT-PCR
Target Length Position AT (8C) Percentage GC Sequence
Vascular endothelial growth factor-A 18 1540e1557 60 56 tgcccgctgctgtctaat
18 1592e1609 60 61 tctccgctctgagcaagg
Placenta growth factor 18 335e352 60 61 ggctgttcccttgcttcc
18 395e412 59 61 cagacaaggcccactgct
Platelet-derived growth factor-BB 18 1108e1125 60 56 tgatctccaacgcctgct
20 1156e1175 59 50 tcatgttcaggtccaactcg
AT, adenine-thymidine; GC, guanine-cytosine.
Figure 1 Viability of primary human retinal pigment epithelium cells
after treatment with the various concentrations of sorafenib, measured
by a colorimetric test (methylthiotetrazole). Untreated retinal pigment
epithelium cells of the same passage served as controls. The results
shown are the mean percentage of control cell survival from three
experiments, each performed in triplicate with error bars indicating SEM.
Sorafenib concentrations of up to 12.5 mg/ml showed no significant
reduction in viability (Wilcoxon with a correction for multiple testing)
compared with controls.
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increase in VEGF-A, PDGF-B and PlGF mRNA expression in RPE
cells (figure 3). Treatment of RPE cells with sorafenib, 1 mg/ml,
directly after light exposure significantly reduced this light-
induced increase in VEGF-A, PDGF-BB and PlGF mRNA after
24 h (figure 3).
Immunohistochemical detection of VEGF-A, PDGF-B and PlGF
expression in RPE Cells
For verification that the light-induced increase in VEGF-A,
PDGF-B and PlGF mRNA transcription translates into increased
protein synthesis, immunohistochemistry was performed 24 h
after illumination.
In both untreated and non-illuminated control cells and cells
that were treated with sorafenib, 1 mg/ml, and had no illumi-
nation, only a faint staining for VEGF-A, PDGF-B and PlGF was
observed (figure 4). After 60 min of light exposure, the expres-
sion of VEGF-A, PDGF-B and PlGF was markedly increased.
In contrast, for RPE cells that were illuminated for 60 min and
had sorafenib at a dose of 1 mg/ml added directly after illumi-
nation, staining showed only a weak expression of VEGF-A,
PDGF-B and PlGF, which was comparable with those cells that
served as non-illuminated controls (figure 4).
Detection of VEGF-A, PDGF-B and PlGF secretion of
human RPE cells
To investigate the effect of sorafenib on VEGF-A, PDGF-BB and
PlGF secretion after light exposure, a quantitative detection of
VEGF-A, PDGF-BB and PlGF in cell-culture supernants was
conducted using the ELISA method 24 h after illumination.
In our experimental set-up, light exposure led to a significant
increase in VEGF-A, PDGF-BB and PlGF in cultured RPE
cells after 60 min of light exposure. In contrast, when cells
were treated with sorafenib, 1 mg/ml, directly after light
exposure, sorafenib treatment decreased the amount of
VEGF-A, PDGF-BB and PlGF significantly compared with those
cells that were not treated with sorafenib after illumination
(figure 5).
DISCUSSION
RPE forms the outer blooderetina barrier to facilitate selective
transport between the choroidal blood vessels and the outer
retina. As a phagocytic system, it is essential for the renewal of
photoreceptors and plays a major role in rod and cone photo-
receptor integrity.1 AMD is a disease of older people population.1
Loss and degeneration of RPE cells, particularly in the macular
centre, is pathognomonic for this disease.1 21 With advancing
age, RPE cells undergo an increase in pleomorphism and accu-
mulate metabolic debris from remnants of incomplete degrada-
tion of phagocytosed rod and cone membranes.1 21 The
incomplete degradation of phagocytosed photoreceptor
membranes results in a continuous increase in intracellular
lipofuscin in the RPE cells over time. This lipofuscin accumu-
lation seems to be associated with deterioration in cellular
function potentially resulting in a higher sensitivity to radiation
damage.22 28e30 Furthermore, the formation of drusen in Bruch
membrane might compromise RPE cell function by impeding
fluid transport and inducing inflammatory responses, which
have been implicated in the development of AMD and
CNV.31e33 Once damaged, RPE cells secrete inadequate amounts
of growth factors, such as VEGF, PDGF, PlGF and others.13e16 An
imbalance between these growth factors in the eye potentially
leads to aberrant angiogenesis resulting in the formation of
dysfunctional blood vessels and CNV.34
Cumulative light exposure is thought to induce proangiogenic
factors in RPE cells and to promote the development of exuda-
tive AMD.16 35 Previous studies have demonstrated that light
exposure can lead to an increased production of VEGF-A in RPE
cells.20 36 37 The reason for this could be that continuous light
exposure induces sublethal cellular stress, which results in an
upregulation of proangiogenic VEGF-A secretion.36
In accordance with these findings, our results clearly indicate
that light exposure not only leads to an upregulation of VEGF-A
but also leads to increased expression and secretion of PDGF-BB
and PlGF in primary human RPE cells.
Figure 2 Viability of primary human retinal pigment epithelium cells
after illumination with plain white light (black column) and after
incubation with sorafenib at a concentration of 1 mg/ml (light grey
column), as measured by a colorimetric test (methylthiotetrazole). The
decrease in cellular viability was significantly reduced when cells were
additionally incubated with sorafenib after 60 min of illumination. Error
bars: SD.
Figure 3 (A) Vascular endothelial growth factor (VEGF)-A, (B) platelet-derived growth factor (PDGF)-BB and (C) placenta growth factor (PlGF) mRNA
expression of primary retinal pigment epithelium cells after illumination with plain white light (black columns) and after incubation with sorafenib at
1 mg/ml (light grey columns), as investigated by quantitative RT-PCR. x-Axis, relative ratio (RR) of VEGF-A, PDGF-BB or PlGF mRNA normalised to 18s
rRNA, expressed in decimal format; y-axis, time of illumination.
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VEGF-A, a member of the VEGF family, is a dimeric 36e46
kDa glycosylated protein with a predominant role in the
development of pathological angiogenesis in AMD.1 7 A
secondary important role of VEGF-A is the induction of
increased vascular permeability.1 6 7 15 16 In RPE cells out of the
macular region of patients with AMD, VEGF-A is significantly
increased, and vitreous VEGF-A levels are significantly higher in
patients with AMD and CNV, compared with healthy control
subjects.38 39 Therefore, VEGF-A has become the main target of
the currently used antiangiogenic agents in the treatment of
AMD.8 However, endothelial cells and pericytes that form the
structure of neovascular tissue seem not to respond to VEGF-A
inhibition alone and currently used anti-VEGF agents seem to
have little effect on existing capillaries.15 16 In addition, not all
attributes of CNV are related to vessels, but many of the
structural abnormalities associated with CNV are related to
fibroblasts, damage of the RPE and the remodelling of the
nascent extracellular matrix.15 16
PlGF, a member of the VEGF family, induces increased
vascular permeability, proliferation, chemotaxis and angiogen-
esis, and may act synergistically with VEGF-A in the develop-
ment of CNV.15 16 Both VEGF-A and PlGF have a recruiting
effect on pericytes during angiogenesis in the maturation process
of endothelial tubes, but also in the early phase of angiogenesis,
where both growth factors act as an integral part of sprouting
capillaries.16 40 41
PDGF-BB, another growth factor expressed by the RPE, acts as
a survival factor for retinal pericytes. PDGF-BB is the key regu-
lator of the pericyte endothelial bond and known to recruit
pericytes in the development of CNV.15 41e43 Pericytes are an
important component of the choroidal neovascular complex,
providing stabilisation of vessels, and are thought to limit the
penetration of anti-VEGF agents.15 41e43 In addition, PDGF is
thought to have an important role in fibroplasia as a wound-
healing response in CNV.15 43 44
Recent studies demonstrated that combined inhibition of
VEGF and PDGF enforces vessel regression by interfering with
pericyte-mediated endothelial cell survival and produced inhibi-
tion and regression of corneal neovascularisation and CNV
compared with anti-VEGF treatment alone.42 43
Therefore, a combined approach of targeting several key
molecules or pathways in a complex disease state as AMDmight
lead to significant improvements in outcome and seems to be
worth while.45
The multikinase inhibitor sorafenib was initially identified as
an RAF kinase inhibitor, but it also inhibits several receptor
Figure 4 Immunohistochemical
staining of vascular endothelial growth
factor (VEGF)-A, platelet-derived
growth factor (PDGF)-B, and placenta
growth factor (PlGF) expression in
retinal pigment epithelium cells. Both
untreated and non-illuminated control
cells and cells that were treated with
sorafenib, 1 mg/ml, and had no
illumination presented only a faint
staining for VEGF-A, PDGF-B and PlGF.
After 60 min of light exposure, the
expression of VEGF-A, PDGF-B and PlGF
was markedly increased. In contrast,
retinal pigment epithelium cells that
were illuminated and had sorafenib
added directly after illumination showed
only a weak staining of VEGF-A, PDGF-B
and PlGF, which was comparable with
those cells that served as
non-illuminated controls.
Figure 5 Inhibitory effect of sorafenib on light-induced secretion of (A) Vascular endothelial growth factor (VEGF)-A, (B) platelet-derived growth
factor (PDGF)-BB and (C) placenta growth factor (PlGF), as investigated by ELISA: untreated retinal pigment epithelium cells after illumination with
plain white light (black columns) and after additional treatment with sorafenib (light grey columns). Each value was normalised to a standard curve of
VEGF-A, PDGF-BB or PlGF and expressed as concentration in nanograms per millilitre. Data values are means6SD.
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tyrosine kinases involved in angiogenesis. Sorafenib’s anti-
proliferative and antiangiogenic efficacy seems to be derived
from its blocking capability of the RAF/mitogen-activated
protein (MAP)/extracellular signal-regulated kinase (ERK) kinase
(MEK)/ERK (RAF/MEK/ERK) cascade and its effect on receptor
tyrosine kinases, including VEGF receptor 2 (VEGFR2), VEGFR3,
PDGF receptor, FLT3, Ret and c-Kit.17 46e49 Furthermore, sora-
fenib interacts with hypoxia-inducible factors 1 and 2 and seems
to have an influence on expression of growth factors, such as
VEGF and PDGF.17 46e48
In this study, sorafenib at a concentration of 1 mg/ml led to
a significant reduction in the light-induced increase in expression
and secretion of VEGF, PlGF, and PDGF in primary human RPE
cells. Moreover, this attenuation of light-induced growth factor
overexpression was accompanied by a significant improvement
of light-induced decrease in RPE cell viability. One potential
reason for this might be that sorafenib not only interacts with
growth factor regulation but also interferes with certain proteins
within the intrinsic apoptotic cascade. The exact mechanisms
are not completely understood; however, it has been demon-
strated for example that sorafenib inhibits the phosphorylation
of the initiation factor eIF4E, which is known to regulate the
translation of a large number of mRNAs, including members so
the Bcl-2 family.17 48 Further research is warranted.
Sorafenib appears to be comparable with systemic anti-VEGF
medications in its safety profile.11 50 The most common side
effects after oral administration in patients treated for renal cell
carcinoma (RCC) were dermatological symptoms such as rash or
handefoot skin reactions, diarrhoea and low-grade hyperten-
sion. Severe adverse events have been described but are rare.50 51
In addition, in our experimental set-up, sorafenib did not have
a significant influence on RPE cell viability after a 24 h exposure
up to a concentration of 12.5 mg/ml. This is more than 10-fold
higher than the sorafenib concentration of 1 mg/ml effective in
our experiments.
The standard dosage of sorafenib as oral treatment for RCC is
800 mg per day. From several clinical trials, we know that after
a daily dose of 800 mg of sorafenib, plasma levels are within the
range of 10 mg/ml, after 200 mg per day around 4.5 mg/ml can be
reached.52e54 To date, there are no data regarding the penetra-
tion of sorafenib into ocular tissue after systemic or after topic
application available, and this issue needs further investigation.
However, the sorafenib concentration of 1 mg/ml effective in
our experiments might be achievable even with a low-dose
treatment.
These data provide the first evidence that sorafenib effectively
interacts in human RPE cells with three important targets of
AMD treatment: VEGF, PlGF and PDGF. Due to its activity
against multiple targets and pathways in angiogenesis, sorafenib
seems to be promising as a potential treatment for AMD.55
Another substantial difference between sorafenib to the
currently used extracellular VEGF inhibitors might be that
the substance potentially acts upstream and downstream in the
angiogenic cascade and therefore potentially prevents tran-
scription and protein production of growth factors in the tissue
from where they are derived.17 55
Recent reports have demonstrated beneficial effects of sora-
fenib in AMD treatment. Kernt et al reported on a patient with
occult CNV who experienced visual improvement and resolu-
tion of macular oedema under oral sorafenib treatment due to
advanced RCC, where intravitreal bevacizumab treatment
failed.19 Other reports describe improvement in visual acuity
under low-dose sorafenib treatment alone or in combination
with intravitreal ranibizumab.18
In this in vitro study sorafenib had a significant impact on
growth-factor expression in the human RPE. The RPE is only
one component interacting in retinal neovascular disease and
not all aspects of mechanisms of action of sorafenib regarding
growth factor expression and signalling are completely under-
stood. Its additional effects on receptor tyrosine kinases and
other cell types involved in the development of AMD need
further investigation. However, the data presented in this in
vitro study indicate that sorafenib provides properties to reduce
light-induced growth factor overexpression in human RPE and,
therefore, might prevent development and progression of CNV
in vivo. Further experimental and clinical studies will have to
substantiate our in vitro findings. Nevertheless, sorafenib seems
to be a promising adjunctive treatment for patients with AMD.
Acknowledgements The authors thank K Obholzer for excellent technical
assistance.
Competing interests None.
Patient consent Obtained.
Ethics approval Ethics approval was provided by the Ludwig-Maximilians-University
Munich.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1. Ehrlich R, Harris A, Kheradiya NS, et al. Age-related macular degeneration and the
aging eye. Clin Interv Aging 2008;3:473e82.
2. Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular degeneration.
the Beaver Dam Eye Study. Arch Ophthalmol 1993;111:514e18.
3. Cruickshanks KJ, Klein R, Klein BE, et al. Sunlight and the 5-year incidence of early
age-related maculopathy: the beaver dam eye study. Arch Ophthalmol
2001;119:246e50.
4. Tomany SC, Cruickshanks KJ, Klein R, et al. Sunlight and the 10-year incidence of
age-related maculopathy: the beaver dam eye study. Arch Ophthalmol
2004;122:750e7.
5. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J
Med 2000;342:483e92.
6. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med
2008;358:2606e17.
7. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo
by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor
chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457e61.
8. Aiello LP. Targeting intraocular neovascularization and edemadone drop at a time.
N Engl J Med 2008;359:967e9.
9. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization:
promises and potential problems. JAMA 2005;293:1509e13.
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-
controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER
Study year 1. Am J Ophthalmol 2008;145:239e48.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related
macular degeneration. N Engl J Med 2006;355:1419e31.
12. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after
an intravitreal injection of bevacizumab (avastin) for macular edema from central
retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336e9.
13. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth
factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin
Endocrinol Diabetes 2000;108:106e9.
14. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and
receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci
1994;35:3649e63.
15. Schlingemann RO. Role of growth factors and the wound healing response in age-
related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91e101.
16. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors
and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1e29.
17. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib,
a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine
kinase signaling. Mol Cancer Ther 2008;7:3129e40.
18. Diago T, Pulido JS, Molina JR, et al. Ranibizumab combined with low-dose sorafenib
for exudative age-related macular degeneration. Mayo Clin Proc 2008;83:231e4.
19. Kernt M, Staehler M, Stief C, et al. Resolution of macular oedema in occult choroidal
neovascularization under oral Sorafenib treatment. Acta Ophthalmol 2008;86:456e8.
20. Kernt M, Neubauer AS, Liegl R, et al. Cytoprotective effects of a blue light-filtering
intraocular lens on human retinal pigment epithelium by reducing phototoxic effects
on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract
Refract Surg 2009;35:354e62.
1538 Br J Ophthalmol 2010;94:1533e1539. doi:10.1136/bjo.2010.182162
Laboratory science
 group.bmj.com on January 21, 2014 - Published by bjo.bmj.comDownloaded from 
21. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of
blue light hazard. Acta Ophthalmol Scand 2006;84:4e15.
22. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new
treatment modalities. Acta Ophthalmol Scand 2002;80:136e43.
23. Holz FG, Pauleikhoff D, Klein R, et al. Pathogenesis of lesions in late age-related
macular disease. Am J Ophthalmol 2004;137:504e10.
24. Barishak YR. In vitro behaviour of the pigmented cells of the retina and uvea of the
adult human eye. Acta Ophthalmol (Copenh) 1960;38:339e46.
25. Flood MT, Gouras P, Kjeldbye H. Growth characteristics and ultrastructure of human
retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci 1980;19:1309e20.
26. Nilsson SE, Sundelin SP, Wihlmark U, et al. Aging of cultured retinal pigment
epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc
Ophthalmol 2003;106:13e16.
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to
proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55e63.
28. Roth F, Bindewald A, Holz FG. Keypathophysiologic pathways in age-related macular
disease. Graefes Arch Clin Exp Ophthalmol 2004;242:710e16.
29. Holz FG, Bellmann C, Margaritidis M, et al. Patterns of increased in vivo fundus
autofluorescence in the junctional zone of geographic atrophy of the retinal pigment
epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp
Ophthalmol 1999;237:145e52.
30. Schutt F, Bergmann M, Holz FG, et al. Isolation of intact lysosomes from human RPE
cells and effects of A2-E on the integrity of the lysosomal and other cellular
membranes. Graefes Arch Clin Exp Ophthalmol 2002;240:983e8.
31. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that
considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s
membrane interface in aging and age-related macular degeneration. Prog Retin Eye
Res 2001;20:705e32.
32. Starita C, Hussain AA, Patmore A, et al. Localization of the site of major resistance to
fluid transport in Bruch’s membrane. Invest Ophthalmol Vis Sci 1997;38:762e7.
33. Moshfeghi DM, Blumenkranz MS. Role of genetic factors and inflammation in age-
related macular degeneration. Retina 2007;27:269e75.
34. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF)
and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with
age-related macular degeneration. Exp Eye Res 2006;82:99e110.
35. Zhou J, Cai B, Jang YP, et al. Mechanisms for the induction of HNE- MDA- and AGE-
adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res
2005;80:567e80.
36. Yanagi Y, Inoue Y, Iriyama A, et al. Effects of yellow intraocular lenses on light-
induced upregulation of vascular endothelial growth factor. J Cataract Refract Surg
2006;32:1540e4.
37. Kernt M, Hirneiss C, Neubauer AS, et al. Protective effect of blue light-absorbing
IOLs on the human retinal pigment epithelium. Ophthalmologe 2010 Feb;107:150e7.
38. Kliffen M, van der Schaft TL, Mooy CM, et al. Morphologic changes in age-related
maculopathy. Microsc Res Tech 1997;36:106e22.
39. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor
are elevated in the vitreous of patients with subretinal neovascularisation. Br J
Ophthalmol 1996;80:363e6.
40. Crocker DJ, Murad TM, Geer JC. Role of the pericyte in wound healing. An
ultrastructural study. Exp Mol Pathol 1970;13:51e65.
41. Schlingemann RO, Oosterwijk E, Wesseling P, et al. Aminopeptidase a is
a constituent of activated pericytes in angiogenesis. J Pathol 1996;179:436e42.
42. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF
signaling enforces tumor vessel regression by interfering with pericyte-mediated
endothelial cell survival mechanisms. Faseb J 2004;18:338e40.
43. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling
enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple
models of ocular neovascularization. Am J Pathol 2006;168:2036e53.
44. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines.
Physiol Rev 2003;83:835e70.
45. Spaide RF. Rationale for combination therapy in age-related macular degeneration.
Retina 2009;29(6 Suppl):S5e7.
46. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar),
a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and
tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol
2006;407:597e612.
47. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits
tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma
model PLC/PRF/5. Cancer Res 2006;66:11851e8.
48. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral
antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine
kinases involved in tumor progression and angiogenesis. Cancer Res
2004;64:7099e109.
49. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET
mutants. J Natl Cancer Inst 2006;98:326e34.
50. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell
carcinoma. N Engl J Med 2007;356:125e34.
51. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized
discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
J Clin Oncol 2006;24:2505e12.
52. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with
advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293e300.
53. Houben R, Voigt H, Noelke C, et al. MAPK-independent impairment of T-cell
responses by the multikinase inhibitor sorafenib. Mol Cancer Ther
2009;8:433e40.
54. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY
43-9006) in combination with oxaliplatin in patients with refractory solid tumors,
including colorectal cancer. Clin Colorectal Cancer 2005;5:188e96.
55. Peyman GA, Fiscella R, Conway M. Combination angiostatic therapies: current
status. Retina 2009;29(6 Suppl):S18e20.
Br J Ophthalmol 2010;94:1533e1539. doi:10.1136/bjo.2010.182162 1539
Laboratory science
 group.bmj.com on January 21, 2014 - Published by bjo.bmj.comDownloaded from 
doi: 10.1136/bjo.2010.182162
 2010 94: 1533-1539Br J Ophthalmol
 
M Kernt, A S Neubauer, R G Liegl, et al.
 
overexpression of VEGF, PDGF and PlGF
epithelium cells from light-induced 
Sorafenib prevents human retinal pigment
 http://bjo.bmj.com/content/94/11/1533.full.html
Updated information and services can be found at: 
These include:
References
 http://bjo.bmj.com/content/94/11/1533.full.html#related-urls
Article cited in: 
 
 http://bjo.bmj.com/content/94/11/1533.full.html#ref-list-1
This article cites 55 articles, 14 of which can be accessed free at:
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (1328 articles)Retina   
 
Articles on similar topics can be found in the following collections
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on January 21, 2014 - Published by bjo.bmj.comDownloaded from 
